Could a single pill tame bipolar depression and obesity together?
NCT ID NCT07699445
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study tests whether the drug lumateperone can improve mood and reduce inflammation in adults with bipolar depression who also have obesity. Over about six weeks, participants take lumateperone daily and undergo mood assessments and an MRI to estimate brain age. The goal is to see if the drug helps both depression and the physical effects of aging linked to obesity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lumateperone
- What this could lead to
- If successful, this could point toward a treatment that addresses both mood and weight-related inflammation in bipolar depression.
- What could go wrong
- This is a small, early-phase study with only 25 participants, so results may not apply broadly. Lumateperone may cause side effects like drowsiness or dizziness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 25 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged 18 to 65 years. 2. Meets DSM-V criteria for Bipolar I Disorder -Depressed without psychosis as confirmed by a semi-structured clinical interview that includes the Mini International Neuropsychiatric Interview. 3. Current episode at least 4 weeks in duration but not longer than 12 months. 4. Depression score \> 20 on the Montgomery Asberg Depression Rating Scale (MADRS). 5. BMI \> 30 6. Capable of providing informed consent. Exclusion Criteria: 1. Meets DSM-V criteria for Schizophrenia, Schizoaffective disorder, or has significant mood-incongruent psychotic symptoms. 2. Young Mania Rating Scale score \>12. 3. Meets DSM-V criteria for rapid cycling. 4. Co-Morbid psychiatric illness, other than generalized anxiety and specific phobias, that in the opinion of the investigator is severe enough that it would likely interfere with the interpretation of changes in the subject's mood state. 5. Meets DSM-V criteria for an active substance use disorder within the past month. 6. Active medical condition that in the opinion of the investigator would contribute to the subject's depressed mood (e.g. hypothyroidism). 7. Significant risk of suicide or self -harm as assessed by clinical interview and the Columbia Suicide Severity Rating Scale (C-SSRS). 8. Significant risk of harm to others as assessed by clinical interview. 9. Pregnancy, or, in women of child-bearing potential, an unwillingness to use an accepted method of birth control for the duration of the study. 10. Current or prior treatment with lumateperone. 11. Moderate or severe hepatic impairment. 12. Current treatment with strong or moderate CYP3A4 inhibitors or CYP3A4 inducers. 13. History of seizure disorder. 14. Significant cardiovascular or cerebrovascular disease that, in the opinion of the investigator, would increase study risk. 15. Dementia-related psychosis. 16. Known hypersensitivity or allergy to lumateperone or any of its components.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar depression depressed phase are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World effectiveness, safety, and Patient-Reported outcomes of tirzepatide in adults with type 2 diabetes mellitus, obesity, or prediabetes in pakistan: a multicentre, prospective, observational cohort study
- Combined inspiratory muscle training and functional High-Intensity interval training promote respiratory, diaphragmatic, and aerobic adaptations in children with obesity
- Relationship between Collagen-Containing supplement use and muscle mass and body image following metabolic and bariatric surgery: a prospective observational study
- Can a dash of spice and protein shield muscle during Weight-Loss shots?
- Could a sirtuin boost make dieting more effective?
- Can a High-Protein or High-Fat Low-Carb diet tame blood sugar and triglycerides?